Halozyme Closes Upsized $1.5B Convertible Notes Offering at 27.5% Conversion Premium
HALO sits 88% above its 52-week low of $61.225 on elevated volume (2.0× avg).
Summary
Halozyme closed its upsized $1.5B convertible notes offering due 2033, using proceeds to fund capped calls and repurchase existing 2027/2028 notes, with conversion set at a 27.5% premium to the pricing reference.
Key Events · Financing and Capital Events · HALO
-
Offering Closed at $1.5B, Upsized from $1.3B
Halozyme completed the sale of $1.5 billion aggregate principal amount of 1.50% Convertible Senior Notes due 2033, including the full $200 million initial purchasers' option, on September 22, 2026.
-
Conversion Premium of 27.5%
Initial conversion rate is 7.1509 shares per $1,000 principal, equivalent to a conversion price of approximately $139.84 per share — a 27.5% premium to the $109.68 reference price at pricing on September 17, 2026.
-
Net Proceeds and Capped Call Cost
Net proceeds were approximately $1,471.1 million after discounts and expenses. Approximately $187.5 million was used to fund capped call transactions with a cap price of $208.39 per share (90% premium).
-
Existing Notes Repurchase
The company expects to repurchase approximately $151.7 million of 2027 Notes and $220.0 million of 2028 Notes for total costs of approximately $217.0 million and $435.5 million, respectively, in privately negotiated transactions.
Analysis · HALO · Life Sciences
Halozyme completed its $1.5 billion convertible senior notes offering, upsized from the $1.3 billion priced just four days ago after the initial purchasers fully exercised their $200 million option. The notes carry a 1.50% coupon and convert at $139.84 per share — a 27.5% premium to the $109.68 reference price at pricing — reflecting strong institutional demand for a company trading near its 52-week high. Net proceeds of roughly $1.47 billion will fund capped call transactions ($187.5M) and repurchase of $371.7M principal of existing 2027 and 2028 convertible notes, reducing near-term dilution overhang while extending maturity to 2033. The capped calls, with a $208.39 cap (90% premium), are designed to offset dilution up to that level. This is a balance-sheet optimization, not a distress raise: Halozyme is using its premium valuation to refinance cheaper, longer-dated debt while protecting shareholders from conversion dilution.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 36.8% of the 985 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HALO was trading at $115.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1B. The 52-week trading range was $61.23 to $115.18. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.